Boston Scientific (BSX) is gaining traction in the emerging markets. New regulatory approvals bode well for the company’s growth. The stock carries a Zacks Rank #2 (Buy) currently.Boston Scientific continues to expand operations across different geographies outside the United States. In 2023, 41% of the company’s consolidated revenues came from international regions.Within its international regions, the company is putting additional efforts to expand its foothold in the emerging markets (defined as all coun ...